The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of obesity and diabetes.

Eli Lilly and Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot.

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes.